Delving into the Latest Updates on KQB-198 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

KQB-198

Target-

Mechanism-

Therapeutic Areas

NeoplasmsHemic and Lymphatic Diseases

Active Indication

Hematologic NeoplasmsAdvanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Kumquat Biosciences, Inc.Startup

Active Organization

Kumquat Biosciences, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:
* What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?
* Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?
* What happens to KQB198 in the body?
Participants will:
* Take KQB198 daily, alone or in combination with another anti-cancer drug
* Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

Start Date01 Dec 2024

Sponsor / Collaborator

Kumquat Biosciences, Inc.Startup

NCT06507306 / RecruitingPhase 1

A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB198 As Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Malignancies

The goal of this clinical trial is to learn if KQB198 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB198. The main questions it aims to answer are:
* What is the safe dose of KQB198 by itself or in combination with other anti-cancer drugs?
* Does KQB198 alone or in combination with other anti-cancer drugs decrease the size of the tumor?
* What happens to KQB198 in the body?
Participants will:
* Take KQB198 daily, alone or in combination with another anti-cancer drug
* Visit the clinic about 8 times in the first 8 weeks, and then once every 4 weeks after that

Start Date03 Jun 2024

Sponsor / Collaborator

Kumquat Biosciences, Inc.Startup

CTIS2024-511453-22-00 / Recruiting

- KQB198-101

Start Date-

Sponsor / Collaborator

Kumquat Biosciences, Inc.Startup

100 Clinical Results associated with KQB-198

Login to view more data

100 Translational Medicine associated with KQB-198

Login to view more data

100 Patents (Medical) associated with KQB-198

Login to view more data

100 Deals associated with KQB-198

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hematologic Neoplasms	Phase 1	US	Kumquat Biosciences, Inc.Startup	01 Dec 2024
Advanced Malignant Solid Neoplasm	Phase 1	US	Kumquat Biosciences, Inc.Startup	03 Jun 2024
Advanced Malignant Solid Neoplasm	Phase 1	ES	Kumquat Biosciences, Inc.Startup	03 Jun 2024
Advanced Malignant Solid Neoplasm	Phase 1	TW	Kumquat Biosciences, Inc.Startup	03 Jun 2024